Purpose: The purpose of this study is to describe the inter‐ and intra‐individual differences in the platelet concentration between blood and platelet‐rich plasma (PRP) preparation, assess intersubject differences considering demographic and anthropometric variables, describe PRP code distribution and analyse intrasubject variability.Methods: A retrospective analysis was conducted using a single‐centre patient database from November 2021 to November 2023. It included patients with musculoskeletal pathologies treated with PRP injections. Primary variables were demographic characteristics (sex, age, body mass index [BMI]) and platelet concentrations in blood and PRP during treatments. Secondary analysis focused on PRP code frequency distribution and intrasubject variability according to different coding systems.Results: Here, 686 patients met the inclusion criteria. PRP exhibited significantly higher platelet concentrations compared to blood (378.01 ± 136.25 × 103 platelets/µL vs. 221.97 ± 58.21 × 103 platelets/µL, p < 0.001). Younger patients had higher platelet concentrations in both blood (p = 0.004) and PRP (p = 0.003), whereas female patients showed higher platelet concentrations only in blood (p < 0.001). The platelet concentration ratio was higher in males (p < 0.001) and those with higher BMI (p = 0.023). Significant differences were found between the existing and modified PRP coding systems (p < 0.001). Intrasubject variability was higher in PRP than in blood (coefficient of variance: 21.32 ± 17.36 in blood vs. 27.85 ± 19.10 in PRP, p < 0.001).Conclusion: Age, gender, BMI and intrasubject variations significantly affect PRP formulation, emphasizing the importance of addressing these variables for a more predictable, personalized and effective therapeutic approach.Level of Evidence: This is a retrospective study. Level IV.
Background/Objectives: The anticoagulant used for blood collection is a fundamental but underexplored variable in platelet-rich plasma (PRP) preparation. Ethylenediaminetetraacetic acid (EDTA) and sodium citrate act on platelets through distinct calcium chelation mechanisms with potentially different consequences for PRP quality. Our group has previously demonstrated that biological and demographic variables independently modulate platelet composition in PRP; the present study extends this analysis to the pre-analytical anticoagulant variable. No prospective paired clinical study has systematically compared the effects of EDTA and sodium citrate on platelet morphological parameters in a real clinical setting. This study aimed to characterise these differences and evaluate their implications for orthobiologic therapy. Methods: A prospective within-subject paired-sample study was conducted at Instituto Cugat—Quirónsalud Barcelona (November 2025–April 2026). Twenty-six consecutive adult patients undergoing routine blood extraction prior to orthopaedic procedures had blood drawn simultaneously into K2-EDTA and sodium citrate (3.2%) tubes. Full haematological analysis was performed on a Sysmex XN automated analyser within 30 min. Primary outcomes were mean platelet volume (MPV), platelet distribution width (PDW), large platelet ratio (P-LCR), large platelet cell count (P-LCC), and plateletcrit (PCT). Statistical comparisons used the paired t-test or Wilcoxon signed-rank test; effect sizes were quantified as Cohen’s d. Results: Seven of eight platelet-related parameters differed significantly between anticoagulants (all p < 0.001). Compared to sodium citrate, EDTA produced systematically higher MPV (+10.1%, d = 2.81), P-LCR (+25.8%, d = 2.41), P-LCC (+24.3%, d = 1.70), PDW (+13.5%, d = 1.33), PCT (+7.3%, d = 0.78), RDW-CV (+2.0%, d = 0.83), and RDW-SD (+2.6%, d = 0.80). MPV was higher with EDTA in all 26/26 paired samples without exception. Total platelet count did not differ significantly (p = 0.135). Effect sizes for all morphological parameters were large (d ≥ 0.78). Conclusions: EDTA is associated with large, reproducible, and universal platelet morphological changes consistent with calcium chelation-induced artefact, not genuine platelet hypertrophy. These artefactual changes systematically overestimate platelet size and large platelet indices by up to 26%, with direct implications for PRP quality assessment in orthobiologic medicine. Sodium citrate should remain the anticoagulant of choice for PRP preparation. Clinicians using EDTA must recognise that morphological parameters do not reflect functional platelet capacity.
Background/Objectives: The anticoagulant used for blood collection is a fundamental but underexplored variable in platelet-rich plasma (PRP) preparation. Ethylenediaminetetraacetic acid (EDTA) and sodium citrate act on platelets through distinct calcium chelation mechanisms with potentially different consequences for PRP quality. Our group has previously demonstrated that biological and demographic variables independently modulate platelet composition in PRP; the present study extends this analysis to the pre-analytical anticoagulant variable. No prospective paired clinical study has systematically compared the effects of EDTA and sodium citrate on platelet morphological parameters in a real clinical setting. This study aimed to characterise these differences and evaluate their implications for orthobiologic therapy. Methods: A prospective within-subject paired-sample study was conducted at Instituto Cugat – Quirónsalud Barcelona (November 2025–April 2026). Twenty-six consecutive adult patients undergoing routine blood extraction prior to orthopaedic procedures had blood drawn simultaneously into K₂-EDTA and sodium citrate (3.2%) tubes. Full haematological analysis was performed on a Sysmex XN automated analyser within 30 minutes. Primary outcomes were mean platelet volume (MPV), platelet distribution width (PDW), large platelet ratio (P-LCR), large platelet cell count (P-LCC), and plateletcrit (PCT). Statistical comparisons used the paired t-test or Wilcoxon signed-rank test; effect sizes were quantified as Cohen's d. Results: Seven of eight platelet-related parameters differed significantly between anticoagulants (all p<0.001). Compared to sodium citrate, EDTA produced systematically higher MPV (+10.1%, d=2.81), P-LCR (+25.8%, d=2.41), P-LCC (+24.3%, d=1.70), PDW (+13.5%, d=1.33), PCT (+7.3%, d=0.78), RDW-CV (+2.0%, d=0.83), and RDW-SD (+2.6%, d=0.80). MPV was higher with EDTA in all 26/26 paired samples without exception. Total platelet count did not differ significantly (p=0.135). Effect sizes for all morphological parameters were large (d≥0.78). Conclusions: EDTA induces large, reproducible, and universal platelet morphological changes consistent with calcium chelation-induced swelling, not genuine platelet hypertrophy. These artefactual changes systematically overestimate platelet size and large platelet indices by up to 26%, with direct implications for PRP quality assessment in orthobiologic medicine. Sodium citrate should remain the anticoagulant of choice for PRP preparation. Clinicians using EDTA must recognise that morphological parameters do not reflect functional platelet capacity.
Intraosseous platelet-rich plasma (IO-PRP) therapy is an emerging biologic approach targeting the osteochondral unit in osteoarthritis (OA), especially of the knee and hip, by addressing subchondral bone pathology implicated in disease progression. This review synthesizes clinical and preclinical evidence on IO-PRP from PubMed and Scopus (up to May 2025), focusing on its biological rationale, therapeutic efficacy, and applications in osteoarticular disease. Evidence from randomized trials, observational studies, and experimental models indicates that IO-PRP – particularly when combined with intra-articular PRP – improves pain, function, and joint structure in moderate-to-severe OA. Preclinical studies demonstrate IO-PRP’s role in subchondral bone remodelling, mesenchymal stromal cell modulation, and inflammation reduction, supporting its disease-modifying potential. IO-PRP represents a promising, biologically grounded intervention for OA management; however, further standardized, long-term clinical trials are needed to determine optimal protocols and validate long-term benefits.
Lateral hinge fracture is a frequent complication of medial opening‐wedge high tibial osteotomy. Previous strategies—such as inserting an additional third Kirschner wire (K‐wire) from the lateral tibial cortex—reinforce the lateral cortex but do not address the potential fracture line that propagates proximally toward the tibial plateau and joint surface. We describe a simple maneuver that reuses the 2 K‐wires routinely employed to guide the osteotomy plane. Once the osteotomy cut is complete, the wires are withdrawn and reinserted horizontally into the proximal metaphyseal tibia, just above the osteotomy gap. Acting as a temporary metaphyseal block, the wires stabilize the epiphyseal‐metaphyseal unit and limit upward fracture propagation into the joint during gradual gap opening. This simple technique is cost‐neutral, reproducible, and complements existing hinge‐protection methods by specifically protecting the articular extension pathway.